Type to search

Health Care Manufacturing & Distribution News

Suicide drug gets FDA fast track

Avatar photo
Share

NeuroRx, a Wilmington biopharmaceutical company, has been granted fast-track status by the U.S. Food and Drug Administration for an experimental treatment for suicidal behavior.

The company will begin enrolling patients in its sequential oral therapy targeting patients admitted to emergency departments with “acute suicidal ideation behavior” in bipolar depression.

The FDA awards Fast Track Designation to experimental drugs the agency deems useful to treat a serious medical condition and fill an unmet medical need.

There is currently no approved drug therapy for suicidal behavior in bipolar depression.

Dr. Jonathan Javitt, CEO of NeuroRx, will update investors on the company’s upcoming clinical trial at the Rodman and Renshaw Global Investment Conference on Monday and Tuesday in New York City.

NeuroRx is privately funded and led by former senior executives of Johnson and Johnson, Pfizer, Lilly, and Bristol Meyer Squibb.

Get the free DBT email newsletter  

Follow the people, companies and issues that matter most to business in Delaware.

Tags:

You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *

Premier Digital Partners

© 2022 Delaware Business Times

Holiday flash sale! Subscribe to Delaware Business Times and save 50%.

Limited time offer. New subscribers only.

Holiday flash sale!

Subscribe to Delaware Business Times and save 50%

Limited time offer. New subscribers only.